

Supplementary material for the article:

Božinović, N.; Šegan, S.; Vojnovic, S.; Pavic, A.; Šolaja, B. A.; Nikodinovic-Runic, J.; Opsenica, I. M. Synthesis and Anti-Candida Activity of Novel Benzothiepine[3,2-c]Pyridine Derivatives. *Chemical Biology and Drug Design* **2016**, 88 (6), 795–806.
<https://doi.org/10.1111/cbdd.12809>

Supporting Information

Synthesis and anti-*Candida* Activity of Novel Benzothiepine[3,2-c]pyridine Derivatives

Nina Božinović,^a Sandra Šegan,^b Sandra Vojnović,^c Aleksandar Pavić,^c Bogdan A. Šolaja,^{*a}
Jasmina Nikodinović-Runic,^{*c} Igor M. Opsenica,^{*a}

^a Faculty of Chemistry, University of Belgrade, Studentski trg 16, P.O. Box 51, 11158, Belgrade, Serbia; *E-mail: bsolaja@chem.bg.ac.rs; igorop@chem.bg.ac.rs

^b Institute of Chemistry, Technology, and Metallurgy, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia

^c Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11000 Belgrade, Serbia; *E-mail: jasmina.nikodinovic@gmail.com; jasmina.nikodinovic@imgge.bg.ac.rs

Table of contents

1. Table S1.....	2
2. Table S2.....	3
3. NMR spectra of representative products.....	4
4. HPLC purity chromatograms.....	21

Table S2. Lethal and teratogenic effects observed in zebrafish (*Danio rerio*) embryos at different hours post fertilization (hpf).

Category	Developmental endpoints	Exposure time (hpf)			
		24	48	72	96
Lethal effect	Egg coagulation ^a	•	•	•	•
	No somite formation	•	•	•	•
	Tail not detached	•	•	•	•
	No heart-beat		•	•	•
Teratogenic effect	Malformation of head	•	•	•	•
	Malformation of eyes ^b	•	•	•	•
	Malformation of sacculi/otoliths ^c	•	•	•	•
	Malformation of chorda	•	•	•	•
	Malformation of tail ^d	•	•	•	•
	Scoliosis	•	•	•	•
	Heart beat frequency		•	•	•
	Blood circulation		•	•	•
	Pericardial edema	•	•	•	•
	Yolk edema	•	•	•	•
	Yolk deformation	•	•	•	•
	Growth retardation ^e	•	•	•	•

^a No clear organs structure are recognized

^b Malformation of eyes was recorded for the retardation in eye development and abnormality in shape and size.

^c Presence of no, one or more than two otoliths per sacculus, as well as reduction and enlargement of otoliths and/or sacculi (otic vesicles).

^d Tail malformation was recorded when the tail was bent, twisted or shorter than to control embryos as assessed by optical comparison.

^e Growth retardation was recorded by comparing with the control embryos in development or size (before hatching, at 24 hpf and 48 hpf) or in a body length (after hatching, at and onwards 72 hpf) using by optical comparison using a inverted microscope (CKX41; Olympus, Tokyo, Japan)

Table S2. Effects of different concentrations of selected thiepines (**4**, **16** and **23**) and **voriconazole** on the development of zebrafish (*Danio rerio*) embryos assessed at 96 hours post fertilization (hpf).




Compound concentration	Dead embryos ^a	Teratogenic embryos ^a	Normal embryos ^a	Growth retardation ^b	Notochord ^b	Eyes ^b	Otoliths ^b	Pericardial edema ^b	Yolk edema ^b	Heart beat ^b	Blood circulation ^b	Hatched ^b	Head malformation ^c	Skeletal deformities ^c	Tail tip ^c
4															
75 µg/ml	10.00	3.33	86.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	96.30	0.00	0.00	3.85
50 µg/ml	3.33	0.00	96.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	96.55	0.00	0.00	0.00
25 µg/ml	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00
10 µg/ml	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00
5 µg/ml	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00
1 µg/ml	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00
16															
75 µg/ml	20.00	80.00	0.00	100.00	0.00	97.92	0.00	52.08	0.00	0.00	0.00	100.00	100.00	97.92	100.00
50 µg/ml	6.67	1.67	86.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	1.89	1.89
25 µg/ml	0.00	1.67	98.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	1.67	0.00
10 µg/ml	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00
5 µg/ml	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00
1 µg/ml	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00
23															
75 µg/ml	100.00	0.00	0.00												
50 µg/ml	33.33	61.67	5.00	0.00	0.00	92.50	0.00	87.50	0.00	0.00	0.00	42.50	100.00	100.00	100.00
25 µg/ml	20.00	53.33	26.67	0.00	0.00	66.67	0.00	58.33	0.00	0.00	0.00	100.00	66.67	50.00	66.67
10 µg/ml	3.33	5.00	91.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	5.17	0.00
5 µg/ml	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00
1 µg/ml	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00
Voriconazole															
75 µg/ml	100.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-
50 µg/ml	100.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-
25 µg/ml	100.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-
10 µg/ml	80.00	20.00	0.00	100.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	0.00
5 µg/ml	36.67	63.33	0.00	100.00	0.00	100.00	100.00	100.00	0.00	0.00	0.00	100.00	100.00	94.74	0.00
1 µg/ml	20.00	60.00	20.00	20.00	100.00	44.44	0.00	55.56	0.00	0.00	0.00	100.00	100.00	55.56	0.00




Abreviation used: (-) data not available due to 100% mortality.



^a Percentage of mortality based on all eggs.




^b Percentage of teratogenic effect based on all alive embryos at the time of assessment.




^c Percentage of teratogenic effect based on all alive hatched embryos at the time of assessment.





























































HPLC analyses for purity

The HPLC analyses were performed in diverse systems:

Method A

Zorbax Eclipse Plus C18 4.6 x 150 mm, 1.8 μ , S.N. USWKY01594 was used as the stationary phase. The eluent was made from the following solvents: 0.2 % formic acid in water (A) and acetonitrile (B). The analysis were performed at the UV max of the compounds (at 270 nm or 300 nm) to maximize selectivity. The compounds were dissolved in dichloromethane or methanol; the final concentrations were $\approx 1 \text{ mg ml}^{-1}$; the flow rate was 0.5 ml min^{-1} .

Compounds **7**, **9**, **10**, **11**, **12** and **19** were eluted using the gradient protocol: 0 – 0.5 min 95 % A, 0.5 - 3 min 95 % A \rightarrow 5 % A, 3 - 13 min 5 % A, 13 – 14 min 5 % A \rightarrow 95 % A, 14 – 16 min 95 % A.

Compound **21** was eluted using the gradient protocol: 0 – 0.5 min 95 % A, 0.5 - 3 min 95 % A \rightarrow 5 % A, 3 - 13 min 5 % A, 13 – 14 min 5 % A \rightarrow 95 % A, 14 – 16 min 95 % A.

Method B

Zorbax Eclipse XDB-C18 4.6 x 50 mm, 1.8 μ , S.N. USWDY02826 was used as the stationary phase. The eluent was made from the following solvents: 0.2 % formic acid in water (A) and acetonitrile (B). The analysis were performed at the UV max of the compounds (at 270 nm or 300 nm) to maximize selectivity. The compounds were dissolved in dichloromethane or methanol; the final concentrations were $\approx 1 \text{ mg ml}^{-1}$; the flow rate was 0.5 ml min^{-1} .

Compounds **7**, **9**, **10**, **11**, **12**, **19** and **21** were eluted using the gradient protocol: 0 – 0.5 min 95 % A, 0.5 - 3 min 95 % A \rightarrow 5 % A, 3 - 13 min 5 % A, 13 – 14 min 5 % A \rightarrow 95 % A, 14 – 16 min 95 % A.

Method C

Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8 μ was used as the stationary phase. The eluent was made from the following solvents: 0.2 % formic acid in water (A) and methanol (B). The analysis were performed at the UV max of the compounds (254 nm or 270 nm) to maximize selectivity. The compounds were dissolved in dichloromethane or methanol; the final concentrations were $\approx 1 \text{ mg ml}^{-1}$; the flow rate was 0.2 ml min^{-1} .




Compounds **14**, **15**, **17**, **18** and **20** were eluted using the gradient protocol: 0 – 0.5 min 95 % A, 0.5 - 3 min 95 % A \rightarrow 5 % A, 3 - 17 min 5 % A, 17 – 19 min 5 % A \rightarrow 95 % A, 19 – 20 min 95 % A.

Method D




Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8 μ was used as the stationary phase. Eluent was made from the following solvents: 0.2 % formic acid in water (A) and acetonitrile (B). The analysis were performed at the UV max of the compounds (254 nm or 270 nm) to maximize

selectivity. The compounds were dissolved in dichloromethane or methanol; the final concentrations were $\approx 1 \text{ mg ml}^{-1}$; the flow rate was 0.2 ml min^{-1} .



Compounds **14**, **15**, **17**, **18** and **20** were eluted using gradient protocol: 0 – 0.5 min 95 % A, 0.5 - 3 min 95 % A \rightarrow 5 % A, 3 - 17 min 5 % A, 17 – 19 min 5 % A \rightarrow 95 % A, 19 – 20 min 95 % A.




HPLC elution profiles for compound **7**, upper method A and lower method B



HPLC elution profiles for compound **9**, upper method A and lower method B





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.757	BV	0.1145	13.58008	1.40229	0.0796
2	6.971	VV	0.1975	108.04030	6.44839	0.6333
3	7.237	VV	0.1217	105.56443	10.33357	0.6188
4	8.165	BV	0.0759	36.92304	7.12745	0.2164
5	8.314	VV	0.0857	18.81927	2.68678	0.1103
6	8.635	VB	0.1138	186.57439	24.50180	1.0936
7	9.106	BB	0.1115	23.38347	2.56277	0.1371
8	9.399	VV	0.0770	9.07039	1.40219	0.0532
9	10.215	BB	0.1126	1.65376e4	2364.83618	96.9390
10	11.516	BB	0.1397	20.24553	1.70851	0.1187




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.830	VB	0.0795	11.91504	1.80633	0.0969
2	5.142	VB	0.0728	18.83530	3.67467	0.1532
3	5.626	BV	0.0798	37.80167	6.85637	0.3075
4	5.803	VB	0.0998	147.77039	23.20591	1.2022
5	6.260	BB	0.1099	30.59805	3.37193	0.2489
6	6.664	VB	0.0833	1.20308e4	2288.28491	97.8794
7	7.335	BB	0.1200	13.73532	1.35751	0.1117

HPLC elution profiles for compound **10**, upper method A and lower method B





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.599	VB	0.0790	40.39238	6.54809	0.1784
2	7.828	VB	0.1219	37.75359	3.65820	0.1668
3	8.296	BB	0.0815	29.30226	4.46598	0.1294
4	8.620	BB	0.0912	26.41581	3.72610	0.1167
5	9.024	BV	0.1000	10.41194	1.27810	0.0460
6	9.500	VB	0.0763	10.84225	1.76174	0.0479
7	10.272	BB	0.1035	2.24850e4	2596.14014	99.3149




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.855	BB	0.3925	241.60541	7.38788	1.1940
2	5.102	BV	0.1190	70.32722	7.92874	0.3476
3	5.521	VV	0.1999	71.45871	4.31143	0.3532
4	5.806	VB	0.1168	51.57803	5.71265	0.2549
5	6.748	BB	0.0717	1.97992e4	3314.19165	97.8503

HPLC elution profiles for compound **11**, upper method A and lower method B





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.888	BB	0.0826	124.82822	20.92245	2.2060
2	8.420	VV	0.0695	60.38920	12.59124	1.0672
3	8.637	VB	0.1036	57.28471	7.41694	1.0124
4	9.397	VV	0.0942	5386.36865	852.95148	95.1895
5	9.979	VB	0.0981	29.70112	4.19751	0.5249




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.731	MM	0.0713	211.61905	49.46984	2.2309
2	5.861	BV	0.0778	152.16524	27.82576	1.6042
3	6.273	BV	0.0710	9068.69238	1959.10767	95.6046
4	6.571	VB	0.0799	53.15163	10.19005	0.5603

HPLC elution profiles for compound **12**, upper method A and lower method B






Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.520	BV	0.0972	639.78992	103.35240	3.0779
2	10.717	VB	0.1059	76.18915	9.12214	0.3665
3	11.335	VB	0.0867	20.35608	3.17935	0.0979
4	11.948	BV	0.0975	206.47504	32.54118	0.9933
5	12.208	VB	0.0923	1.98205e4	2916.68823	95.3538
6	14.309	BB	0.0909	22.95485	3.17439	0.1104





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.549	VB	0.1609	133.01857	9.86188	0.6552
2	7.746	BB	0.0768	104.59921	19.89641	0.5152
3	8.362	VV	0.0793	45.45561	8.44947	0.2239
4	8.757	BV	0.0811	578.63983	109.66137	2.8503
5	10.560	BV	0.0794	1.94261e4	2929.59204	95.6911
6	11.275	VB	0.0812	13.03478	1.90850	0.0642


HPLC elution profiles for compound **14**, upper method C and lower method D



HPLC elution profiles for compound **15**, upper method C and lower method






Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.366	BV	0.1353	12.97182	1.15296	0.0555
2	11.347	BB	0.1142	44.75092	5.72373	0.1915
3	11.786	BB	0.0883	12.53788	1.68475	0.0537
4	12.204	BV	0.0908	336.30023	57.87526	1.4391
5	12.384	VV	0.0918	2.22633e4	2891.74512	95.2718
6	13.078	VB	0.2712	667.29565	31.61833	2.8556
7	14.219	BB	0.0965	31.04912	3.81115	0.1329





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.561	BB	0.3611	228.75266	7.62266	1.0879
2	7.716	BB	0.0905	91.60204	14.05607	0.4356
3	8.126	BB	0.0872	52.91157	9.11221	0.2516
4	9.519	BV	0.0955	37.20607	5.35729	0.1769
5	9.692	VV	0.0732	21.58880	4.21589	0.1027
6	9.860	VB	0.0793	13.60892	2.16578	0.0647
7	10.169	BB	0.0657	7.50022	1.47720	0.0357
8	10.474	BV	0.0838	2.04148e4	3003.15430	97.0852
9	11.025	VV	0.0998	60.92194	7.82446	0.2897
10	11.327	VB	0.1053	98.82442	13.59944	0.4700


HPLC elution profiles for compound **17**, upper method C and lower method D



HPLC elution profiles for compound **18**, upper method C and lower method D






Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.994	BV	0.0637	19.01350	4.08923	0.0778
2	9.130	VB	0.0831	77.64167	13.30229	0.3176
3	9.446	BV	0.0743	29.46633	4.82399	0.1205
4	9.562	VB	0.0708	24.73343	4.22413	0.1012
5	9.842	BV	0.1091	84.75491	10.02737	0.3467
6	10.001	VB	0.0929	77.84397	12.21028	0.3184
7	10.363	BV	0.1162	262.28683	33.73746	1.0728
8	10.749	VV	0.1749	477.60129	42.55501	1.9534
9	10.950	VV	0.0680	18.32907	3.71904	0.0750
10	11.243	VB	0.1290	2.32843e4	2731.29443	95.2355
11	11.909	BB	0.1013	93.22077	13.38474	0.3813




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.107	BV	0.1371	108.18636	10.20858	0.6448
2	6.090	BV	0.0357	5.25130	1.93432	0.0313
3	6.221	VB	0.0562	55.25375	14.93462	0.3293
4	6.535	BV	0.0730	47.25948	10.30827	0.2817
5	6.821	BV	0.0654	175.72183	40.65167	1.0473
6	6.916	VV	0.0917	330.94272	50.35007	1.9725
7	7.199	VV	0.0800	1.59925e4	3060.41846	95.3179
8	7.556	VB	0.0686	62.94118	14.22441	0.3751


HPLC elution profiles for compound **19**, upper method A and lower method B




HPLC elution profiles for compound **20**, upper method C and lower method D



21



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.612	BB	0.0757	56.75945	10.63887	0.7516
2	4.836	BV	0.0700	13.15713	2.30685	0.1742
3	5.199	VV	0.1460	95.34753	8.36601	1.2626
4	5.506	VV	0.0890	7285.84912	1250.28284	96.4829
5	6.162	VV	0.1297	43.96879	4.26788	0.5823
6	6.408	VV	0.1012	30.50436	3.66132	0.4040
7	6.563	VB	0.1427	25.85148	2.25607	0.3423



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.937	BB	0.0631	6.39481	1.30638	0.0873
2	4.132	BV	0.0738	108.18619	21.29767	1.4776
3	4.308	VV	0.0951	117.23798	17.07328	1.6012
4	4.536	VV	0.0755	7028.17334	1452.48560	95.9883
5	4.928	VV	0.1118	33.59949	3.72330	0.4589
6	5.144	VB	0.1044	22.40838	2.71325	0.3060
7	6.260	BB	0.0633	5.90258	1.15082	0.0806

HPLC elution profiles for compound **21**, upper method A and lower method B